New antifungal drug could shield liver transplant patients from deadly infections
NCT ID NCT06774144
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new antifungal drug called rezafungin can prevent serious fungal infections in people who have had a liver transplant. About 385 adults at high risk for infection will receive the drug, and their outcomes will be compared to similar patients from the past two years. The goal is to see if rezafungin reduces infections and improves survival without harming the new liver.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Presbyterian
Pittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can one Mega-Dose of an antifungal beat a deadly infection in AIDS patients?
- New score could help doctors spot fungal pneumonia faster
- Transplant breakdown? new study checks organ fluid for hidden germs
- New blood test may help protect kids from post-transplant infection
- New gel shows promise for ugly toenail fungus
- Hidden virus threat in dual organ transplants revealed